Ticker

Analyst Price Targets — SKIN

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
May 20, 2026 12:24 pmRoth Capital$2.00$0.69TheFly Beauty Health price target lowered to $2 from $2.50 at Roth Capital
May 1, 2026 10:48 amCanaccord Genuity$1.00$0.85TheFly Beauty Health price target lowered to $1 from $1.50 at Canaccord
January 14, 2026 11:33 amJefferies$1.60$1.53TheFly Beauty Health assumed with a Hold at Jefferies
September 19, 2025 9:04 amGeorge KellyRoth Capital$3.50$2.37TheFly Beauty Health initiated with a Buy at Roth Capital
May 5, 2025 12:00 pmSusan AndersonCanaccord Genuity$1.25$1.06TheFly Beauty Health price target lowered to $1.25 from $1.50 at Canaccord
March 13, 2025 10:53 amCanaccord Genuity$1.50$1.34TheFly Beauty Health price target lowered to $1.50 from $1.75 at Canaccord
August 9, 2024 8:49 amKorinne WolfmeyerPiper Sandler$1.00$1.14StreetInsider The Beauty Health Company (SKIN) PT Lowered to $1 at Piper Sandler
May 10, 2024 8:22 amKorinne WolfmeyerPiper Sandler$2.50$3.26StreetInsider The Beauty Health Company (SKIN) PT Lowered to $2.50 at Piper Sandler
March 13, 2024 6:42 amKorinne WolfmeyerPiper Sandler$3.00$4.25StreetInsider The Beauty Health Company (SKIN) PT Raised to $3 at Piper Sandler
March 13, 2024 4:34 amJonathan BlockStifel Nicolaus$4.00$4.25StreetInsider The Beauty Health Company (SKIN) PT Raised to $4 at Stifel

Latest News for SKIN

Herbalife (NYSE:HLF) versus Beauty Health (NASDAQ:SKIN) Head to Head Comparison

Herbalife (NYSE: HLF - Get Free Report) and Beauty Health (NASDAQ: SKIN - Get Free Report) are both small-cap consumer staples companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, dividends and valuation. Volatility and Risk Herbalife has a beta

Defense World • Aug 11, 2026
Beauty Health Q2 Earnings Call Highlights

Beauty Health NASDAQ: SKIN reported second-quarter revenue at the low end of its guidance range as cautious capital spending by providers continued to weigh on equipment sales, while stronger gross margins and expense discipline lifted adjusted EBITDA above expectations.

MarketBeat • Aug 7, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for SKIN.

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top